KURA

Kura Oncology, Inc.

A clinical-stage biopharmaceutical company developing targeted precision medicines for solid tumors and blood cancers. Its investigational drug tipifarnib and approved oral medicine ziftomenib (KOMZIFTI) treat acute myeloid leukemia and other cancers, used by patients who have few other options. Founded in 2014, the company takes its name from the Kura River in southwestern Asia, a nod to the river-themed naming of its founders' earlier firm, Araxes Pharma — chosen because the Kura eventually flows into the Araxes, symbolizing drugs that work "downstream" of the RAS cancer pathway.